Table 1.

FDA-approved medication use for all individuals with SCD and those with an average of 2 or more pain episodes in every 12-month period

Medication	All individuals with SCD	Individuals with SCD and 2 or more pain episodes in a year
Hydroxyurea	24.6% (n = 1957/7957)	31.5% (n = 1428/4531)
L-glutamine	2.0% (n = 149/7345)	3.2% (n = 135/4191)
Voxelotor	1.9% (n = 101/5304)	2.9% (n = 85/2888)
Crizanlizumab	1.4% (n = 72/5304)	2.3% (n = 65/2888)
Hydroxyurea + L-glutamine	1.2% (n = 86/7345)	1.8% (n = 76/4191)
Hydroxyurea + Voxelotor	1.0%(n = 55/5304)	1.6% (n = 46/2888)
Hydroxyurea + crizanlizumab	0.6% (n = 34/5304)	1.1% (n = 33/2888)
Crizanlizumab + L-glutamine	0.1% (n = 5/5304)	0.2% (n = 5/2888)
Hydroxyurea + L-glutamine + crizanlizumab	<0.1% (n = 3/5304)	0.1% (n = 3/2888)

Denominators are based on eligible participants when medications were approved by the FDA.